Organ preservation, for rectal cancer: general overview of the latest data from phase III randomized trials
DOI:
https://doi.org/10.2340/1651-226X.2025.41057Keywords:
Rectal cancer, organ preservation, contact x-ray therapyAbstract
Introduction: Organ preservation (OP) strategies are gaining interest in improving the quality of life in the management of rectal cancer, particularly for tumors located in the distal or middle rectum. The optimal OP protocol is still not standardized and relies on randomized trials. This review summarizes past and ongoing studies on OP protocols for adenocarcinoma of the distal and middle rectum.
Method: We searched for articles and abstracts on randomized clinical trials investigating OP approaches for rectal cancer, including data presented at the LUCARRE Congress held in Nice on November 25, 2023, covering ongoing and recently published trials on rectal preservation.
Results: Our review’s findings are presented in four tables: the first evaluates key trials with overall survival (OS) as the primary endpoint; the second provides an overview of past Phase III trials; the third reviews Phase II/III trials that specifically focus on local excisions (LE); and finally, the fourth summarizes ongoing trials. Each table is accompanied by detailed comments elucidating the significance and implications of the presented data, alongside a review of current guidelines.
Interpretation: We highlight the growing interest in OP strategies for rectal cancer management to enhance patients’ quality of life. Despite the lack of international consensus on the optimal OP protocol, past and ongoing randomized trials provide valuable findings into the evolving management strategies of rectal cancer treatment. The presented data supports the role of randomized phase III trials to provide evidence for a change in clinical practice.
Downloads
References
Heald RJ, Ryall RDH. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet. 1986;327(8496):1479–82.
https://doi.org/10.1016/S0140-6736(86)91510-2 DOI: https://doi.org/10.1016/S0140-6736(86)91510-2
Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rödel C, Cervantes A, et al. Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv22–40.
https://doi.org/10.1093/annonc/mdx224 DOI: https://doi.org/10.1093/annonc/mdx224
Weiser MR. AJCC 8th edition: colorectal cancer. Ann Surg Oncol. 2018;25(6):1454–5.
https://doi.org/10.1245/s10434-018-6462-1 DOI: https://doi.org/10.1245/s10434-018-6462-1
Ali F, Keshinro A, Weiser MR. Advances in the treatment of locally advanced rectal cancer. Ann Gastroenterol Surg. 2021;5(1):32–8.
https://doi.org/10.1002/ags3.12389 DOI: https://doi.org/10.1002/ags3.12389
Gerard JP, Barbet N, Schiappa R, Magné N, Martel I, Mineur L, et al. Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2–cT3 rectal adenocarcinoma (OPERA): a phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol. 2023;8(4):356–67.
https://doi.org/10.1016/S2468-1253(22)00392-2 DOI: https://doi.org/10.1016/S2468-1253(22)00392-2
Serra-Aracil X, Pericay C, Badia-Closa J, Golda T, Biondo S, Hernández P, et al. Short-term outcomes of chemoradiotherapy and local excision versus total mesorectal excision in T2–T3ab,N0,M0 rectal cancer: a multicentre randomised, controlled, phase III trial (the TAU-TEM study). Ann Oncol. 2023;34(1):78–90.
https://doi.org/10.1016/j.annonc.2022.09.160 DOI: https://doi.org/10.1016/j.annonc.2022.09.160
Schrag D, Shi Q, Weiser MR, Gollub MJ, Saltz LB, Musher BL, et al. Preoperative treatment of locally advanced rectal cancer. N Engl J Med. 2023;389(4):322–34.
https://doi.org/10.1056/NEJMoa2303269 DOI: https://doi.org/10.1056/NEJMoa2303269
Conroy T, Bosset JF, Etienne PL, Rio E, François É, Mesgouez-Nebout N, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(5):702–15.
https://doi.org/10.1016/S1470-2045(21)00079-6 DOI: https://doi.org/10.1016/S1470-2045(21)00079-6
Bahadoer RR, Dijkstra EA, Van Etten B, Marijnen CAM, Putter H, Kranenbarg EMK, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):29–42. DOI: https://doi.org/10.1016/S1470-2045(20)30555-6
Garcia-Aguilar J, Patil S, Gollub MJ, Kim JK, Yuval JB, Thompson HM, et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol. 2022;40(23):2546–56. DOI: https://doi.org/10.1200/JCO.22.00032
Juul T, Ahlberg M, Biondo S, Emmertsen KJ, Espin E, Jimenez LM, et al. International validation of the low anterior resection syndrome score. Ann Surg. 2014;259(4):728–34.
https://doi.org/10.1097/SLA.0b013e31828fac0b DOI: https://doi.org/10.1097/SLA.0b013e31828fac0b
Fokas E, Appelt A, Glynne-Jones R, Beets G, Perez R, Garcia-Aguilar J, et al. International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer. Nat Rev Clin Oncol. 2021;18(12):805–16.
https://doi.org/10.1038/s41571-021-00538-5 DOI: https://doi.org/10.1038/s41571-021-00538-5
Bujko K, Polish Colorectal Study Group. Neoadjuvant chemoradiation for fixed cT3 or cT4 rectal cancer: results of a Polish II multicenter phase III study. J Clin Oncol. 2016;34(4_suppl):489.
https://doi.org/10.1200/jco.2016.34.4_suppl.489 DOI: https://doi.org/10.1200/jco.2016.34.4_suppl.489
Jin J, Tang Y, Hu C, Jiang LM, Jiang J, Li N, et al. Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR). J Clin Oncol. 2022;40(15):1681–92. DOI: https://doi.org/10.1200/JCO.2021.39.15_suppl.3510
https://doi.org/10.1200/JCO.21.01667 DOI: https://doi.org/10.1200/JCO.21.01667
Erlandsson J, Lörinc E, Ahlberg M, Pettersson D, Holm T, Glimelius B, et al. Tumour regression after radiotherapy for rectal cancer – results from the randomised Stockholm III trial. Radiother Oncol. 2019;135:178–86.
https://doi.org/10.1016/j.radonc.2019.03.016 DOI: https://doi.org/10.1016/j.radonc.2019.03.016
François E, De Bari B, Ronchin P, Nouhaud E, Martel-Lafay I, Artru P, et al. Comparison of short course radiotherapy with chemoradiotherapy for locally advanced rectal cancers in the elderly: a multicentre, randomised, non-blinded, phase 3 trial. Eur J Cancer. 2023;180:62–70.
https://doi.org/10.1016/j.ejca.2022.11.020 DOI: https://doi.org/10.1016/j.ejca.2022.11.020
Bosset JF, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, et al. Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results – EORTC 22921. J Clin Oncol. 2005;23(24):5620–7.
https://doi.org/10.1200/JCO.2005.02.113 DOI: https://doi.org/10.1200/JCO.2005.02.113
Garant A, Kavan P, Martin AG, Azoulay L, Vendrely V, Lavoie C, et al. Optimizing treatment sequencing of chemotherapy for patients with rectal cancer: the KIR randomized phase II trial. Radiother Oncol. 2021;155:237–245.
https://doi.org/10.1016/j.radonc.2020.11.008 DOI: https://doi.org/10.1016/j.radonc.2020.11.008
Fokas E, Schlenska-Lange A, Polat B, Klautke G, Grabenbauer GG, Fietkau R, et al. Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for patients with locally advanced rectal cancer: long-term results of the CAO/ARO/AIO-12 randomized clinical trial. JAMA Oncol. 2022;8(1):e215445.
Appelt AL, Pløen J, Harling H, Jensen FS, Jensen LH, Jørgensen JCR, et al. High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study. Lancet Oncol. 2015;16(8):919–27.
https://doi.org/10.1016/S1470-2045(15)00120-5 DOI: https://doi.org/10.1016/S1470-2045(15)00120-5
Garcia-Aguilar J, Renfro LA, Chow OS, Shi Q, Carrero XW, Lynn PB, et al. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial. Lancet Oncol. 2015;16(15):1537–46.
https://doi.org/10.1016/S1470-2045(15)00215-6 DOI: https://doi.org/10.1016/S1470-2045(15)00215-6
Rullier E, Vendrely V, Asselineau J, Rouanet P, Tuech JJ, Valverde A, et al. Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial. Lancet Gastroenterol Hepatol. 2020;5(5):465–74.
https://doi.org/10.1016/S2468-1253(19)30410-8 DOI: https://doi.org/10.1016/S2468-1253(19)30410-8
Bach SP, Gilbert A, Brock K, Korsgen S, Geh I, Hill J, et al. Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study. Lancet Gastroenterol Hepatol. 2021;6(2):92–105. DOI: https://doi.org/10.1016/S2468-1253(20)30333-2
Stijns RCH, De Graaf EJR, Punt CJA, Nagtegaal ID, Nuyttens JJME, Van Meerten E, et al. Long-term oncological and functional outcomes of chemoradiotherapy followed by organ-sparing transanal endoscopic microsurgery for distal rectal cancer: the CARTS study. JAMA Surg. 2019;154(1):47.
https://doi.org/10.1001/jamasurg.2018.3752 DOI: https://doi.org/10.1001/jamasurg.2018.3752
Kennecke HF, O’Callaghan CJ, Loree JM, Moloo H, Auer R, Jonker DJ, et al. Neoadjuvant chemotherapy, excision, and observation for early rectal cancer: the phase II NEO trial (CCTG CO.28) primary end point results. J Clin Oncol. 2023;41(2):233–42.
https://doi.org/10.1200/JCO.22.00184 DOI: https://doi.org/10.1200/JCO.22.00184
Bennett H, Rao C, Batten L, Hasler E, Jarrom D, Prettyjohns M, et al. Low energy contact X‐ray brachytherapy for treatment of rectal cancer: a health technology appraisal by Health Technology Wales. Colorectal Dis. 2024;26(5):1053–8.
https://doi.org/10.1111/codi.16935 DOI: https://doi.org/10.1111/codi.16935
Joseph DA, Johnson CJ, White A, Wu M, Coleman MP. Rectal cancer survival in the United States by race and stage, 2001 to 2009: findings from the CONCORD‐2 study. Cancer. 2017;123(S24):5037–58.
https://doi.org/10.1002/cncr.30882 DOI: https://doi.org/10.1002/cncr.30882
El Sissy C, Kirilovsky A, Van Den Eynde M, Muşină AM, Anitei MG, Romero A, et al. A diagnostic biopsy-adapted immunoscore predicts response to neoadjuvant treatment and selects patients with rectal cancer eligible for a watch-and-wait strategy. Clin Cancer Res. 2020;26(19):5198–207.
https://doi.org/10.1158/1078-0432.CCR-20-0337 DOI: https://doi.org/10.1158/1078-0432.CCR-20-0337
Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, et al. PD-1 blockade in mismatch repair–deficient, locally advanced rectal cancer. N Engl J Med. 2022;386(25):2363–76.
https://doi.org/10.1056/NEJMoa2201445 DOI: https://doi.org/10.1056/NEJMoa2201445
Grotenhuis BA, Beets GL. Watch-and-wait is an option in rectal cancer patients: from controversy to common clinical practice. Clin Oncol. 2023;35(2):124–9.
https://doi.org/10.1016/j.clon.2022.11.011 DOI: https://doi.org/10.1016/j.clon.2022.11.011
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Syrine Ben Dhia, Damien Chauviere, Diana Mitrea, Renaud Schiappa, Tanguy Pace Loscos , Emmanuel Chamorey , David Baron
This work is licensed under a Creative Commons Attribution 4.0 International License.
